Project Grant H8G47580

The National Science Foundation (NSF) awarded a $997,689 Cooperative Agreement under its NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Omnicyte LLC, a minority-owned small business in Branford, CT. The funding supports the design and production of a next-generation COVID-19 vaccine that addresses weaknesses of current vaccines, such as reduced booster effectiveness, short-lived efficacy, and side effects. The project aims to develop a vaccine candidate with improved...

This $799,904 Cooperative Agreement award, granted by the Centers for Disease Control and Prevention (CDC) under the Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) program (CFDA 93.323), supports research and activities by New York University (NYU) School of Medicine to study vaccine hesitancy and uptake. The award, effective from September 30, 2024 through September 29, 2029, will enable NYU to serve as a coordinating and collaborating center for this CDC initiative, which...

This federal Project Grant award of $442,478.00, awarded by the National Science Foundation (NSF) under the Social, Behavioral, and Economic Sciences (CFDA 47.075) program, supports a multi-modal study on sociodemographic influences on vaccine decision-making. The research team, led by the University of California, Los Angeles (UCLA) with a sub-award to Arizona State University (ASU), will examine how local illness models, individual factors, sociodemographic characteristics, and social learning...

This $737,761.00 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) aims to enhance HIV prevention with a vaccine approach that promotes durable immunity. The key products and services to be delivered include: Detailed immune analyses to uncover mechanisms of effective T follicular helper (Tfh) cell-mediated humoral immunity against HIV, using both DNA and mRNA vaccine platforms in rhesus macaques. The...

This Project Grant award of $2,065,719 from the National Institute on Minority Health and Health Disparities (NIMHD), under the Minority Health and Health Disparities Research (CFDA 93.307) program, will fund a community-based behavioral intervention study to increase COVID-19 and influenza vaccination among African American/Black and Latino persons. The study, led by New York University (NYU) in partnership with the Northern Manhattan Improvement Corporation, will use a multiphase...

The U.S. Centers for Disease Control and Prevention (CDC) awarded a $282,526 Cooperative Agreement under the Immunization Cooperative Agreements (CFDA 93.268) program to the South Carolina Department of Public Health (SCDPH) to administer the Behavioral Risk Factor Surveillance System in South Carolina. The 5-year award, effective August 1, 2024 through July 31, 2029, will fund SCDPH's efforts to establish and maintain preventive health service programs focused on immunizing individuals...

This $820,000 Cooperative Agreement award from the Centers for Disease Control and Prevention (CDC) under the "CDC Investigations and Technical Assistance" program (CFDA 93.283) will support "Strengthening Routine Immunization and Vaccine Equity (STRIVE)" activities in the Democratic Republic of the Congo and Brazil. The 5-year project, with a period of performance from September 30, 2024 to September 29, 2029, will be implemented by the non-profit organization World Vision...

The Centers for Disease Control and Prevention (CDC) awarded a five-year, $48,244,515 Cooperative Agreement to the Virginia State Board of Health (VA SBOH) through the Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health program (CFDA 93.421). This grant funding will support VA SBOH's Office of Emergency Preparedness Division in delivering a range of critical public health, emergency response, and social service programs across...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $3,056,673 to The Johns Hopkins University to conduct research on improving hepatitis B vaccine responses in people living with HIV. The key objectives are to: Define the innate immune signatures induced by the HEPLISAV-B vaccine (containing the CPG 1018 adjuvant) compared to the standard ENGERIX-B vaccine, and...

This Cooperative Agreement award, funded by the Centers for Disease Control and Prevention (CDC) Investigations and Technical Assistance program (CFDA 93.283), provides $1,980,000.00 to Jhpiego Corp to strengthen immunization program implementation in the Philippines. The 5-year project, commencing on September 30, 2024, aims to improve the delivery of critical immunization services and enhance the overall health system capacity at the subnational level. Jhpiego, a non-profit global health...